The results of xelox (capecitabine plus oxaliplatin) in metastatic colorectal cancer: A single center experience

被引：0
|
作者：
Yaman, Emel [1 ]
Yildiz, Ramazan [1 ]
Kaya, A. Osman [1 ]
Ozturk, Banu [1 ]
Buyukberber, Suleyman [1 ]
Coskun, Ugur [1 ]
Benekli, Mustafa [1 ]
Yamac, Deniz [1 ]
Uner, Aytug [1 ]
机构：
[1] Gazi Med Fac, Ankara, Turkey
来源：
ANNALS OF ONCOLOGY | 2006年 / 17卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：129 / 129
页数：1
相关论文
共 50 条
  • [41] Cetuximab plus capecitabine/irinotecan (XELIRI) versus cetuximab plus capecitabine/oxaliplatin (XELOX) as first line treatment for patients with metastatic colorectal cancer (CRC): A randomized trial of the AIO CRC study group
    Von Weikersthal, Ludwig Fischer
    Moosmann, Nicolas
    Vehling-Kaiser, U.
    Stauch, Martina
    Schlimok, G.
    Schulze, M.
    Walther, J.
    Weiss, J.
    Dietzfelbinger, H.
    Heinemann, Volker
    ANNALS OF ONCOLOGY, 2006, 17 : 115 - 115
  • [42] Phase I pharmacokinetic study of chronomodulated dose-intensified combination of capecitabine and oxaliplatin (XELOX) in metastatic colorectal cancer
    Mohamad Farid
    Balram Chowbay
    Xiangai Chen
    Sze Huey Tan
    Saminathan Ramasamy
    Wen Hsin Koo
    Han Chong Toh
    Su Pin Choo
    Simon Yew Kuang Ong
    Cancer Chemotherapy and Pharmacology, 2012, 70 : 141 - 150
  • [43] Phase II study of biweekly XELOX (capecitabine and oxaliplatin) as first line chemotherapy in elderly patients with metastatic colorectal cancer
    Grande, C., Sr.
    Quintero, G.
    Mel, J. R.
    Huidobro, G.
    Campos, B.
    Candamio, S.
    Mendez, J. C.
    Salgado, M.
    Alvarez, E.
    Casal, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [44] Cost-effectiveness of capecitabine in combination with oxaliplatin (XELOX) compared with FOLFOX for the treatment of metastatic colorectal cancer: A Canadian evaluation
    Belovich, D.
    Hux, M.
    Douglas, P.
    Maroun, J. A.
    Sommer, N.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [45] Capecitabine and oxaliplatin (XELOX) as first-line treatment for elderly patients (pts) with advanced/metastatic colorectal cancer (MCRC)
    Salud, A.
    Escudero, P.
    Feliu, J.
    Lopez-Gomez, L.
    Bolanos, M.
    Galan, A.
    Yubero, A.
    Vicent, J. M.
    Losa, F.
    Gonzalez-Baron, M.
    EJC SUPPLEMENTS, 2005, 3 (02): : 190 - 190
  • [46] Phase II study of short-course capecitabine plus oxaliplatin (XELOX) followed by maintenance capecitabine in advanced colorectal cancer: XelQuali study
    Waddell, T.
    Gollins, S.
    Soe, W.
    Valle, J.
    Allen, J.
    Bentley, D.
    Morris, J.
    Lloyd, A.
    Swindell, R.
    Taylor, M. B.
    Saunders, M. P.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2011, 67 (05) : 1111 - 1117
  • [47] Phase I pharmacokinetic study of chronomodulated dose-intensified combination of capecitabine and oxaliplatin (XELOX) in metastatic colorectal cancer
    Farid, Mohamad
    Chowbay, Balram
    Chen, Xiangai
    Tan, Sze Huey
    Ramasamy, Saminathan
    Koo, Wen Hsin
    Toh, Han Chong
    Choo, Su Pin
    Ong, Simon Yew Kuang
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2012, 70 (01) : 141 - 150
  • [48] Capecitabine (X) following short-course capecitabine plus oxaliplatin (XELOX) in advanced colorectal cancer (CRC): Phase II XelQuali study
    Soe, W.
    Gollins, S.
    Waddell, T.
    Valle, J. W.
    Allen, J.
    Bentley, D.
    Morris, J.
    Lloyd, A.
    Swindell, R.
    Saunders, M. P.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [49] RANDOMIZED PHASE II STUDY OF OXALIPLATIN AND S-1 (OS) VERSUS OXALIPLATIN AND CAPECITABINE (XELOX) IN PATIENTS WITH METASTATIC OR RECURRENT COLORECTAL CANCER
    Zang, D. Y.
    Chung, I. J.
    Oh, H.
    Park, K. U.
    Lee, K. H.
    Han, B.
    Choi, D. R.
    Kim, H. S.
    Kim, J. H.
    ANNALS OF ONCOLOGY, 2012, 23 : 193 - 193
  • [50] Phase II study of short-course capecitabine plus oxaliplatin (XELOX) followed by maintenance capecitabine in advanced colorectal cancer: XelQuali study
    T. Waddell
    S. Gollins
    W. Soe
    J. Valle
    J. Allen
    D. Bentley
    J. Morris
    A. Lloyd
    R. Swindell
    M. B. Taylor
    M. P. Saunders
    Cancer Chemotherapy and Pharmacology, 2011, 67 : 1111 - 1117
12345